NASDAQ:DTIL - Get Free Report ) is set to post its quarterly earnings results before the market opens on Monday, May 13th. Analysts expect Precision BioSciences to post earnings of ($0.45) per share for the quarter.
Get Precision BioSciences alerts:
Sign Up
Precision BioSciences (NASDAQ:DTIL - Get Free Report ) last issued its quarterly earnings results on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The business had revenue of $7.04 million during the quarter, compared to analyst estimates of $28.50 million. Precision BioSciences had a negative net margin of 125.84% and a negative return on equity of 204.66%. On average, analysts expect Precision BioSciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Precision BioSciences Stock Performance Shares of Precision BioSciences stock traded up $0.70 on Wednesday, reaching $11.27. 90,635 shares of the company's stock were exchanged, compared to its average volume of 117,579. The firm's 50-day moving average is $12.34 and its two-hundred day moving average is $11.85. The company has a market capitalization of $77.99 million, a P/E ratio of -0.70 and a beta of 1.62. Precision BioSciences has a 52 week low of $8.25 and a 52 week high of $27.02.
Analysts Set New Price Targets A number of research firms have commented on DTIL. Guggenheim began coverage on shares of Precision BioSciences in a report on Tuesday, April 30th. They issued a "buy" rating and a $19.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, April 17th.
Check Out Our Latest Analysis on DTIL
About Precision BioSciences (
Get Free Report )
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Further Reading
Before you consider Precision BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.
While Precision BioSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
